{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T16:26:09Z","timestamp":1782923169877,"version":"3.54.5"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2015,9,17]],"date-time":"2015-09-17T00:00:00Z","timestamp":1442448000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2015,9,17]],"date-time":"2015-09-17T00:00:00Z","timestamp":1442448000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1007\/s10637-015-0289-4","type":"journal-article","created":{"date-parts":[[2015,9,17]],"date-time":"2015-09-17T02:48:33Z","timestamp":1442458113000},"page":"1271-1279","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Blinatumomab for the treatment of acute lymphoblastic leukemia"],"prefix":"10.1007","volume":"33","author":[{"given":"Jason B.","family":"Kaplan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Grischenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis J.","family":"Giles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,9,17]]},"reference":[{"issue":"1","key":"289_CR1","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1182\/blood-2011-04-347872","volume":"119","author":"M Dores","year":"2012","unstructured":"Dores M, Devesa SS, Curtis RE, Linet MS, Morton LM (2012) Acute leukemia incidence and patient survival among children and adults in the United States. Blood 119(1):2001\u20137","journal-title":"Blood"},{"issue":"1","key":"289_CR2","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3322\/caac.21208","volume":"64","author":"R Siegel","year":"2014","unstructured":"Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics, 2014. CA Cancer J Clin 64(1):9\u201329","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"289_CR3","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","volume":"114","author":"JW Vardiman","year":"2009","unstructured":"Vardiman JW, Arber DA, Brunning RD et al (2009) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia : rationale and important changes. Blood 114(5):937\u201351","journal-title":"Blood"},{"issue":"8","key":"289_CR4","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.1182\/blood-2006-10-051912","volume":"109","author":"AV Moorman","year":"2007","unstructured":"Moorman AV, Harrison CJ, Buck GA et al (2007) Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII\/Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood 109(8):3189\u201397","journal-title":"Blood"},{"key":"289_CR5","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) Acute Lymphoblastic Leukemia [Internet]. NCCN 2014. Available from: http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/all.pdf"},{"issue":"24","key":"289_CR6","doi-asserted-by":"publisher","first-page":"3880","DOI":"10.1200\/JCO.2009.26.9456","volume":"28","author":"DA Thomas","year":"2010","unstructured":"Thomas DA, O\u2019Brien S, Faderl S et al (2010) Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol 28(24):3880\u20139","journal-title":"J Clin Oncol"},{"issue":"21","key":"289_CR7","first-page":"170","volume":"116","author":"D Hoelzer","year":"2010","unstructured":"Hoelzer D, Huettmann A, Kaul F et al (2010) Immunochemotherapy with rituximab improves molecular CR rate and outcome in CD20+ B-lineage standard and high risk patients; results of 263 CD20+ patients studied prospectively in GMALL study 07\/2003. ASH Annu Meet Abstr 116(21):170","journal-title":"ASH Annu Meet Abstr"},{"issue":"1","key":"289_CR8","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3109\/10428194.2012.708753","volume":"54","author":"J-M Ribera","year":"2013","unstructured":"Ribera J-M (2013) Optimal approach to treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: how to best use all the available tools. Leuk Lymphoma 54(1):21\u20137","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"289_CR9","doi-asserted-by":"publisher","first-page":"222","DOI":"10.3324\/haematol.2012.063602","volume":"98","author":"D Pulte","year":"2013","unstructured":"Pulte D, Redaniel MT, Jansen L, Brenner H, Jeffreys M (2013) Recent trends in survival of adult patients with acute leukemia: overall improvements, but persistent and partly increasing disparity in survival of patients from minority groups. Haematologica 98(2):222\u20139","journal-title":"Haematologica"},{"issue":"3","key":"289_CR10","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1053\/j.seminhematol.2013.06.007","volume":"50","author":"C-H Pui","year":"2013","unstructured":"Pui C-H, Evans WE (2013) A 50-year journey to cure childhood acute lymphoblastic leukemia. Semin Hematol 50(3):185\u201396, Elsevier","journal-title":"Semin Hematol"},{"issue":"5","key":"289_CR11","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1182\/blood-2008-01-130237","volume":"112","author":"W Stock","year":"2008","unstructured":"Stock W, La M, Sanford B et al (2008) What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children\u2019s Cancer Group and Cancer and Leukemia Group B studies. Blood 112(5):1646\u201354","journal-title":"Blood"},{"issue":"1","key":"289_CR12","doi-asserted-by":"publisher","first-page":"95","DOI":"10.2174\/138945010790031063","volume":"11","author":"B Ten Cate","year":"2010","unstructured":"Ten Cate B, de Bruyn M, Wei Y, Bremer E, Helfrich W (2010) Targeted elimination of leukemia stem cells; a new therapeutic approach in hemato-oncology. Curr Drug Targets 11(1):95\u2013110","journal-title":"Curr Drug Targets"},{"issue":"23","key":"289_CR13","doi-asserted-by":"publisher","first-page":"4470","DOI":"10.1182\/blood-2012-06-379040","volume":"120","author":"M Bruggemann","year":"2012","unstructured":"Bruggemann M, Raff T, Kneba M (2012) Has MRD monitoring superseded other prognostic factors in adult ALL? Blood 120(23):4470\u201381","journal-title":"Blood"},{"issue":"3","key":"289_CR14","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1182\/blood-2006-05-018192","volume":"109","author":"AK Fielding","year":"2007","unstructured":"Fielding AK, Richards SM, Chopra R et al (2007) Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12\/ECOG 2993 study. Blood 109(3):944\u201350","journal-title":"Blood"},{"issue":"11","key":"289_CR15","doi-asserted-by":"publisher","first-page":"3186","DOI":"10.1002\/cncr.23919","volume":"113","author":"S O\u2019Brien","year":"2008","unstructured":"O\u2019Brien S, Thomas D, Ravandi F et al (2008) Outcome of adults with acute lymphocytic leukemia after second salvage therapy. Cancer 113(11):3186\u201391","journal-title":"Cancer"},{"key":"289_CR16","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-014-0210-9","author":"H Dombret","year":"2014","unstructured":"Dombret H, Cluzeau T, Huguet F, Boissel N (2014) Pediatric-like therapy for adults with ALL. Curr Hematol Malig Rep. doi:10.1007\/s11899-014-0210-9","journal-title":"Curr Hematol Malig Rep"},{"issue":"4","key":"289_CR17","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.clml.2013.03.015","volume":"13","author":"M Wetzler","year":"2013","unstructured":"Wetzler M, Thomas DA, Wang ES et al (2013) Phase I\/II trial of nanomolecular liposomal annamycin in adult patients with relapsed\/refractory acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk 13(4):430\u20134, Elsevier Inc","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"8","key":"289_CR18","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/j.ctrv.2013.03.006","volume":"39","author":"P Robak","year":"2013","unstructured":"Robak P, Robak T (2013) Older and new purine nucleoside analogs for patients with acute leukemias. Cancer Treat Rev 39(8):851\u201361, Elsevier Ltd","journal-title":"Cancer Treat Rev"},{"key":"289_CR19","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13205","author":"J Ai","year":"2014","unstructured":"Ai J, Advani A (2014) Current status of antibody therapy in ALL. Br J Haematol. doi:10.1111\/bjh.13205, 1\u201310","journal-title":"Br J Haematol"},{"key":"289_CR20","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1182\/asheducation-2013.1.131","volume":"2013","author":"AS Advani","year":"2013","unstructured":"Advani AS (2013) New immune strategies for the treatment of acute lymphoblastic leukemia: antibodies and chimeric antigen receptors. Hematol Am Soc Hematol Educ Program 2013:131\u20137","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"4","key":"289_CR21","doi-asserted-by":"publisher","first-page":"e128","DOI":"10.3324\/haematol.2014.120220","volume":"100","author":"P Chevallier","year":"2014","unstructured":"Chevallier P, Huguet F, Raffoux E et al (2014) Vincristine, dexamethasone and epratuzumab for older relapsed\/refractory CD22+ B-acute lymphoblastic leukemia patients: a Phase 2 Study. Haematologica 100(4):e128\u201331","journal-title":"Haematologica"},{"issue":"16","key":"289_CR22","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","volume":"368","author":"SA Grupp","year":"2013","unstructured":"Grupp SA, Kalos M, Barrett D et al (2013) Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 368(16):1509\u201318","journal-title":"N Engl J Med"},{"issue":"16","key":"289_CR23","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude SL, Frey N, Shaw PA et al (2014) Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 371(16):1507\u201317","journal-title":"N Engl J Med"},{"issue":"1","key":"289_CR24","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/ni1547","volume":"9","author":"D Depoil","year":"2008","unstructured":"Depoil D, Fleire S, Treanor BL et al (2008) CD19 is essential for B cell activation by promoting B cell receptor-antigen microcluster formation in response to membrane-bound ligand. Nat Immunol 9(1):63\u201372","journal-title":"Nat Immunol"},{"key":"289_CR25","doi-asserted-by":"crossref","first-page":"244","DOI":"10.4049\/jimmunol.131.1.244","volume":"131","author":"LM Nadler","year":"1983","unstructured":"Nadler LM, Anderson KC, Marti G et al (1983) B4, a human B lymphocyte-associated antigen expressed on normal, mitogen-activated, and malignant B lymphocytes. J Immunol 131:244\u201350","journal-title":"J Immunol"},{"issue":"1","key":"289_CR26","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/2162-3619-1-36","volume":"1","author":"K Wang","year":"2012","unstructured":"Wang K, Wei G, Liu D (2012) CD19: a biomarker for B cell development, lymphoma diagnosis and therapy. Exp Hematol Oncol 1(1):36","journal-title":"Exp Hematol Oncol"},{"key":"289_CR27","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1126\/science.1373518","volume":"256","author":"RH Carter","year":"1992","unstructured":"Carter RH, Fearon DT (1992) CD19: lowering the threshold for antigen receptor stimulation of B lymphocytes. Science 256:105\u20137","journal-title":"Science"},{"key":"289_CR28","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1056\/NEJMoa051568","volume":"354","author":"MC Van Zelm","year":"2006","unstructured":"Van Zelm MC, Reisli I, van der Burg M et al (2006) An antibody-deficiency syndrome due to mutations in the CD19 gene. N Engl J Med 354:1901\u201312","journal-title":"N Engl J Med"},{"issue":"June","key":"289_CR29","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.3109\/10428194.2011.559668","volume":"52","author":"S Raponi","year":"2011","unstructured":"Raponi S, De Propris MS, Intoppa S et al (2011) Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases. Leuk Lymphoma 52(June):1098\u2013107","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"289_CR30","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood.V71.1.13.13","volume":"71","author":"FM Uckun","year":"1988","unstructured":"Uckun FM, Jaszcz W, Ambrus JL et al (1988) Detailed studies on expression and function of CD19 surface determinant by using B43 monoclonal antibody and the clinical potential of anti-CD19 immunotoxins. Blood 71(1):13\u201329","journal-title":"Blood"},{"key":"289_CR31","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1182\/blood.V79.9.2201.2201","volume":"79","author":"FM Uckun","year":"1992","unstructured":"Uckun FM, Manivel C, Arthur D et al (1992) In vivo efficacy of B43 (anti-CD19)-pokeweed antiviral protein immunotoxin against human pre-B cell acute lymphoblastic leukemia in mice with severe combined immunodeficiency. Blood 79:2201\u201314","journal-title":"Blood"},{"key":"289_CR32","first-page":"1105","volume":"44","author":"P Mitchell","year":"2003","unstructured":"Mitchell P, Lee F-T, Hall C et al (2003) Targeting primary human Ph(+) B-cell precursor leukemia-engrafted SCID mice using radiolabeled anti-CD19 monoclonal antibodies. J Nucl Med 44:1105\u201312","journal-title":"J Nucl Med"},{"issue":"3","key":"289_CR33","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.pharmthera.2012.07.013","volume":"136","author":"D Nagorsen","year":"2012","unstructured":"Nagorsen D, Kufer P, Baeuerle PA, Bargou R (2012) Blinatumomab: a historical perspective. Pharmacol Ther 136(3):334\u201342, Elsevier Inc","journal-title":"Pharmacol Ther"},{"issue":"1","key":"289_CR34","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1093\/intimm\/dxu089","volume":"27","author":"Z Zimmerman","year":"2014","unstructured":"Zimmerman Z, Maniar T, Nagorsen D (2014) Unleashing the clinical power of T cells: CD19\/CD3 bi-specific T cell engager (BiTE\u00ae) antibody construct blinatumomab as a potential therapy. Int Immunol 27(1):31\u20137","journal-title":"Int Immunol"},{"issue":"6012","key":"289_CR35","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1038\/314628a0","volume":"314","author":"UD Staerz","year":"1985","unstructured":"Staerz UD, Kanagawa O, Bevan MJ (1985) Hybrid antibodies can target sites for attack by T cells. Nature 314(6012):628\u201331, England","journal-title":"Nature"},{"issue":"July","key":"289_CR36","doi-asserted-by":"publisher","first-page":"7021","DOI":"10.1073\/pnas.92.15.7021","volume":"92","author":"M Mack","year":"1995","unstructured":"Mack M, Riethm\u00fcller G, Kufer P (1995) A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity. Proc Natl Acad Sci U S A 92(July):7021\u20135","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"289_CR37","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.cbpa.2013.03.029","volume":"17","author":"SR Frankel","year":"2013","unstructured":"Frankel SR, Baeuerle PA (2013) Targeting T cells to tumor cells using bispecific antibodies. Curr Opin Chem Biol 17(3):385\u201392, Elsevier Ltd","journal-title":"Curr Opin Chem Biol"},{"issue":"6","key":"289_CR38","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1002\/ijc.10557","volume":"100","author":"T Dreier","year":"2002","unstructured":"Dreier T, Lorenczewski G, Brandl C et al (2002) Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody. Int J Cancer 100(6):690\u20137","journal-title":"Int J Cancer"},{"issue":"1","key":"289_CR39","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/ijc.20908","volume":"115","author":"P Hoffmann","year":"2005","unstructured":"Hoffmann P, Hofmeister R, Brischwein K et al (2005) Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-\/CD3-bispecific single-chain antibody construct. Int J Cancer 115(1):98\u2013104","journal-title":"Int J Cancer"},{"key":"289_CR40","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1146\/annurev.immunol.25.022106.141609","volume":"25","author":"GA Rabinovich","year":"2007","unstructured":"Rabinovich GA, Gabrilovich D, Sotomayor EM (2007) Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 25:267\u201396","journal-title":"Annu Rev Immunol"},{"key":"289_CR41","doi-asserted-by":"crossref","unstructured":"Schub A, Nagele V, Zugmaier G, et al (2013) Immunopharmacodynamic response to blinatumomab in patients with relapsed\/refractory B-precursor acute lymphoblastic leukemia (ALL). J Clin Oncol (suppl; abstr 7020)","DOI":"10.1200\/jco.2013.31.15_suppl.7020"},{"issue":"10","key":"289_CR42","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1007\/s00262-007-0298-z","volume":"56","author":"C Brandl","year":"2007","unstructured":"Brandl C, Haas C, D\u2019Argouges S et al (2007) The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19\/CD3-bispecific single-chain antibody construct. Cancer Immunol Immunother 56(10):1551\u201363","journal-title":"Cancer Immunol Immunother"},{"issue":"8","key":"289_CR43","doi-asserted-by":"publisher","first-page":"4397","DOI":"10.4049\/jimmunol.170.8.4397","volume":"170","author":"T Dreier","year":"2003","unstructured":"Dreier T, Baeuerle PA, Fichtner I et al (2003) T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-\/CD3- bispecific single-chain antibody construct. J Immunol 170(8):4397\u2013402","journal-title":"J Immunol"},{"key":"289_CR44","unstructured":"Onyx Pharmaceuticals (2015) BLINCYTO (blinatumomab) Prescribing Information"},{"issue":"15_suppl","key":"289_CR45","first-page":"3048","volume":"31","author":"B Wu","year":"2013","unstructured":"Wu B, Hijazi Y, Wolf A, Brandl C, Sun Y-N, Zhu M (2013) Pharmacokinetics (PK) of blinatumomab and its clinical implications. ASCO Meet Abstr 31(15_suppl):3048","journal-title":"ASCO Meet Abstr"},{"issue":"9","key":"289_CR46","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.yexcr.2011.03.010","volume":"317","author":"D Nagorsen","year":"2011","unstructured":"Nagorsen D, Baeuerle PA (2011) Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab. Exp Cell Res 317(9):1255\u201360, Elsevier Inc","journal-title":"Exp Cell Res"},{"key":"289_CR47","unstructured":"FDA Drug Approval Package [Internet]. [cited 2015 Mar 2]. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/125557Orig1s000TOC.cfm"},{"issue":"Abstract 302","key":"289_CR48","first-page":"197","volume":"31","author":"M-E Goebeler","year":"2013","unstructured":"Goebeler M-E, Viardot A, Kufer P, Topp MS, Knop S, Mackensen L (2013) Final results from a phase 1 study of blinatumomab in patients with relapsed\/refractory Non-Hodgkin\u2019s lymphoma. Hematol Oncol 31(Abstract 302):197","journal-title":"Hematol Oncol"},{"issue":"Abstract PH-P54","key":"289_CR49","first-page":"S361","volume":"37","author":"F Locatelli","year":"2014","unstructured":"Locatelli F, Gore L, Zugmaier G, Handgretinger R, Rizzari C, Trippett T (2014) Blinatumomab in pediatric patients with Relapsed\/Refractory (R\/R) B-cell Precursor Acute Lymphoblastic Leukaemia (BCP-ALL): a phase I\/II study. Bone Marrow Transplant 37(Abstract PH-P545):S361","journal-title":"Bone Marrow Transplant"},{"issue":"18","key":"289_CR50","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1200\/JCO.2010.32.7270","volume":"29","author":"MS Topp","year":"2011","unstructured":"Topp MS, Kufer P, G\u00f6kbuget N et al (2011) Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol 29(18):2493\u20138","journal-title":"J Clin Oncol"},{"issue":"26","key":"289_CR51","doi-asserted-by":"publisher","first-page":"5185","DOI":"10.1182\/blood-2012-07-441030","volume":"120","author":"MS Topp","year":"2012","unstructured":"Topp MS, G\u00f6kbuget N, Zugmaier G et al (2012) Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood 120(26):5185\u20137","journal-title":"Blood"},{"issue":"36","key":"289_CR52","doi-asserted-by":"publisher","first-page":"4134","DOI":"10.1200\/JCO.2014.56.3247","volume":"32","author":"MS Topp","year":"2014","unstructured":"Topp MS, Gokbuget N, Zugmaier G et al (2014) Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol 32(36):4134\u201340","journal-title":"J Clin Oncol"},{"key":"289_CR53","first-page":"57","volume":"15","author":"MS Topp","year":"2014","unstructured":"Topp MS, G\u00f6kbuget N, Stein AS et al (2014) Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol 15:57\u201366","journal-title":"Lancet Oncol"},{"issue":"21","key":"289_CR54","doi-asserted-by":"crossref","first-page":"Abstract 379","DOI":"10.1182\/blood.V124.21.379.379","volume":"124","author":"N Goekbuget","year":"2014","unstructured":"Goekbuget N, Dombret H, Bonifacio M et al (2014) BLAST: a confirmatory, single-Arm, phase 2 study of blinatumomab, a Bispecific T-cell Engager (BiTE\u00ae) antibody construct, in patients with minimal residual disease B-precursor Acute Lymphoblastic Leukemia (ALL). Blood 124(21):Abstract 379","journal-title":"Blood"},{"issue":"6","key":"289_CR55","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1517\/14712598.2015.1009888","volume":"15","author":"M Ruella","year":"2015","unstructured":"Ruella M, Gill S (2015) How to train your T cell: genetically engineered chimeric antigen receptor T cells versus bispecific T-cell engagers to target CD19 in B acute lymphoblastic leukemia. Expert Opin Biol Ther 15(6):761\u20136","journal-title":"Expert Opin Biol Ther"},{"issue":"1","key":"289_CR56","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/S1470-2045(14)71183-0","volume":"16","author":"X Thomas","year":"2014","unstructured":"Thomas X (2014) Blinatumomab: a new era of treatment for adult ALL? Lancet Oncol 16(1):6\u20137, Elsevier Ltd","journal-title":"Lancet Oncol"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-015-0289-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-015-0289-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-015-0289-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-015-0289-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T04:48:17Z","timestamp":1678510097000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-015-0289-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,17]]},"references-count":56,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["289"],"URL":"https:\/\/doi.org\/10.1007\/s10637-015-0289-4","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,17]]},"assertion":[{"value":"10 August 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}